Osaka, Japan

Toshiomi Yoshida


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Toshiomi Yoshida - Innovating Glycoprotein Production

Introduction

Toshiomi Yoshida, an accomplished inventor based in Osaka, Japan, has made significant contributions to the field of biotechnology. Known for his innovative methods in glycoprotein production, Yoshida stands out in the realm of transgenic plant cell technology.

Latest Patents

Yoshida holds a patent for a groundbreaking method titled "Method of co-expressing galactosyltransferase and a glycoprotein in a transgenic plant cell and sialylating the glycoprotein for production of glycoprotein having human-type sugar chain." This innovative technique involves the introduction of a gene for an enzyme that facilitates the addition of galactose to the sugar chain of a glycoprotein. By transforming plant cells and culturing them, Yoshida’s method allows for the recovery of glycoproteins with human-type sugar chains, significantly enhancing the potential for medical applications.

Career Highlights

Yoshida's career is marked by his dedication to advancing glycoprotein production techniques. His work at Phyton Holdings, LLC, underscores his commitment to harnessing the capabilities of transgenic technology to create more effective biopharmaceuticals. This method not only boosts efficiency in glycoprotein production but also promises to improve the therapeutic value of these proteins.

Collaborations

Throughout his career, Toshiomi Yoshida has collaborated with esteemed colleagues such as Kazuhito Fujiyama and Tatsuji Seki. Together, they share a vision of leveraging plant biotechnology to address complex challenges in medicine, pushing the boundaries of what is possible in the production of therapeutically relevant glycoproteins.

Conclusion

Toshiomi Yoshida’s contributions to the field of biotechnology through his innovative patents exemplify the power of creativity in science. With his dedicated work at Phyton Holdings, LLC, and valuable collaborations, Yoshida continues to pave the way for advancements in glycoprotein production, impacting the landscape of biopharmaceutical development. His pioneering methods not only hold promise for enhanced drug efficacy but also exemplify the future of transgenic technology in addressing global health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…